Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Article
en En
| MEDLINE
| ID: mdl-37855036
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Haematologica
Año:
2023
Tipo del documento:
Article